

**Clinical Pharmacy Program Guidelines for Lysteda**

Program	Prior Authorization
Medication	Lysteda (tranexamic acid)
Issue Date	9/2010
Pharmacy and Therapeutics Approval Date	9/2017
Effective Date	11/2017

**1. Background:**

Lysteda is indicated for the treatment of cyclic heavy menstrual bleeding.

**2. Coverage Criteria:**

<p><b>A. Lysteda will be approved based on the following criteria:</b></p> <p>1. History of failure, contraindication, or intolerance to hormonal contraceptive/hormone replacement product</p> <p align="center"><b>-AND-</b></p> <p>2. Diagnosis with cyclic heavy menstrual bleeding.</p> <p><b>Authorization will be issued for 12 months.</b></p>
--

**3. References:**

1. Lysteda [package insert]. Newport, KY: Xanodyne Pharmaceuticals; March 2016..
2. National Collaborating Centre for Women's and Children's Health. Heavy menstrual bleeding. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2007 Jan. 164 p.
3. American College of Obstetricians and Gynecologists (ACOG). Noncontraceptive uses of hormonal contraceptives. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2010 Jan. 13 p. (ACOG practice bulletin; no. 110).
4. American College of Obstetricians and Gynecologists (ACOG). Intrauterine device. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2005 Jan. 10 p. (ACOG practice bulletin; no. 59).
5. Singh S, Best C, Dunn S, et al. Abnormal Uterine Bleeding in Pre-Menopausal Women. J Obstet Gynaecol. 2013;35(5):473–475.



Community Plan

6. Rogers M, Ludkin H, Jones S. Treatment of Heavy Menstrual Bleeding. University of Huddersfield. Independent Nurse. 2014. <http://eprints.hud.ac.uk/20292/>.

Program	Prior Authorization – Lysteda
<b>Change Control</b>	
Date	Change
9/2010	New policy
9/2011	Step therapy change to prior authorization due to inability of claims system to properly render step therapy logic.
9/2012	Annual Review
12/2015	Annual Review
10/2016	Updated language to align with standard UHC try/fail requirements. Clinical intent of the criteria remain unchanged.
9/2017	Added diagnosis check. Updated references.

